TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

GENOSCIENCE PHARMA

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

GENOSCIENCE PHARMA

ST13

US500000079258665

Classe

1, 5, 42, 44

Pedido

79258665

Registro

6132420

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

31

Atualização mais recente

26/08/2025

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

1, 5, 42, 44

Data de depósito

01/02/2019

Data de registro

25/08/2020

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

25/08/2020

Última transação

26/08/2025

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

34

Localização do titular

FR

Examinador

EULIN, INGRID

Unidade examinadora

M20

Localização atual

PUBLICATION AND ISSUE SECTION

Titulares e representantes

Titulares

G. P. (pessoa física)

Representantes

James R. Robinson Robinson Law Office, PLLC

Classificação técnica

Classes Nice

Classe 1Classe 5Classe 42Classe 44

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 1

Active chemical ingredients used in the manufacture of anti-cancer drugs; chemical products intended for pharmaceutical sciences, namely, chemical additives for use in the manufacture of pharmaceuticals; preserving agents for the pharmaceutical industry, namely, preservatives for use in the pharmaceutical industry; antioxidants for the manufacture of pharmaceutical products; chemical preparations for be used in the manufacture of pharmaceutical products, namely, active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer-related diseases or conditions; chemicals for use in biotechnological product development; enzymes derived from biotechnological processes for industrial use; chemicals used in biotechnological manufacturing processes; diagnostic preparations and diagnostic reagents for scientific or research use; reagents and solvents for sample preparation, modification and manipulation of cells, as well as for the implementation of marking methods, separation, isolation, reproduction and/or cleaning of biopolymers, nucleic acids, proteins, macromolecules, namely, reagents for scientific use and biologically active substances for diagnostic use, namely, biologically active enzymes and microorganisms that are aimed as sanitizing water environments and to treat the activation and optimization of biological filter systems

Classe 5

Pharmaceutical preparations, pharmaceutical products, and pharmaceutical substances, namely, pharmaceutical preparations for the treatment of cancer-related diseases or conditions; pharmaceutical preparations for cancer treatment; biopharmaceutical products for cancer treatment, namely, biological preparations for the treatments of cancer; pharmaceutical products for cancer treatment; pharmaceutical preparations and substances for cancer prevention; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for cancer prevention and treatment; biotechnological preparations for medical use, namely, biological tissue cultures for medical purposes; diagnostic agents for medical use; strips for medical diagnosis, namely, medical diagnostic test strips for cancer diagnosis; diagnostic preparations for medical use; diagnostic reagents for medical use; diagnostic substances for medical use; pharmaceutical medicine products and diagnostic products for sample preparation, modification and manipulation of cells and for marking, separation, isolation, reproduction and/or cleaning of biopolymers, nucleic acids, proteins, macromolecules and biologically active substances, namely, chemical reagents for medical purposes

Classe 42

Development of new technology on behalf of third parties in the field of genetics and biotechnology; biotechnological processes for regulating, modifying and characterizing of disease conditions, medical research specialized in the biotechnological field with respect to regulating, modifying and characterizing diseases or conditions; research and development for third parties in the field of biotechnology; manufacturing and consolidating upon request of DNA, biological organisms, cells, viruses, pathogens, special cells which have been genetically modified according to the specification of third parties for scientific, medical and laboratory use and for research, namely, medical and scientific laboratory services; gene therapy services for third parties, namely, scientific research and product development regarding DNA, biological organisms, cells, viruses, pathogens and special cells which have been genetically modified for scientific and medical use and for research; scientific and technological services, namely, research and design in the field of medical treatment, namely, cancer treatment; industrial analysis and research services, namely, testing, analysis and evaluation of drugs for treatment of cancer and cancer-related diseases and conditions to assure compliance with industry and regulatory standards; research and development of anti-cancer drugs; development of pharmaceutical preparations and medicines; development of pharmaceutical products; development of chemical compounds, namely, custom design and development of reagents and biochemical assays; research and development of new products for others with respect to chemical compounds for therapeutic use; pharmaceutical drug development services for anti-cancer drugs; evaluation of pharmaceutical products; research in the field of pharmaceutical products, namely, pharmaceutical research and development; pharmaceutical research and development in the field of anti-cancer drugs; pharmaceutical research and development services; pharmaceutical research; carrying out clinical trials for pharmaceutical products, namely, conducting clinical trials for others; conducting cancer treatment clinical trials for others; provision of medical and scientific research information concerning the results of clinical trials for pharmaceutical products; laboratory research services in the field of pharmaceuticals; laboratory research services for cancer treatment; testing, inspection and research services in the field of pharmaceuticals; testing, inspection and research for pharmaceuticals for cancer treatment; biotechnological research services; preparation of reports in the field of biotechnology; research and development in the field of biotechnology; services provided by consultants in the field of biotechnology, namely, scientific research consulting in the field of biotechnology; providing scientific research information in the biochemical and biotechnological fields; product design and development in the field of medical and pharmaceutical diagnostic apparatus

Classe 44

Medical analysis services for diagnosing cancer; medical analysis of RNA or DNA for cancer diagnosis and prognosis; medical analysis services for cancer diagnosis and prognosis; colorectal cancer screening services; medical services for diagnosing diseases; medical diagnosis of cancer-related diseases or conditions; medical testing for the diagnosis and treatment of persons; medical analysis services for cancer diagnosis; medical testing and analysis for diagnostic or treatment purposes

Publicações

Histórico de despachos e eventos da marca no USPTO.

31 publicações encontradas

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

25/08/2025

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

03/01/2021

FICS

FINAL DISPOSITION NOTICE SENT TO IB

16/12/2020

FIMP

FINAL DISPOSITION PROCESSED

15/12/2020

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

25/11/2020

R.PR

REGISTERED-PRINCIPAL REGISTER

25/08/2020

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

09/06/2020

PUBO

PUBLISHED FOR OPPOSITION

09/06/2020

GPNX

NOTIFICATION PROCESSED BY IB

05/06/2020

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

20/05/2020

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

20/05/2020

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

20/05/2020

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

04/05/2020

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

30/04/2020

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

30/04/2020

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

30/04/2020

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

13/01/2020

GNFR

FINAL REFUSAL E-MAILED

13/01/2020

CNFR

FINAL REFUSAL WRITTEN

13/01/2020

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

18/12/2019

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

18/12/2019

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

18/12/2019

RFNT

REFUSAL PROCESSED BY IB

12/07/2019

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

24/06/2019

RFRR

REFUSAL PROCESSED BY MPU

24/06/2019

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

04/06/2019

CNRT

NON-FINAL ACTION WRITTEN

03/06/2019

MAFR

APPLICATION FILING RECEIPT MAILED

24/05/2019

DOCK

ASSIGNED TO EXAMINER

20/05/2019

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

20/05/2019

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

16/05/2019

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace GENOSCIENCE PHARMA ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.